A Pancreatic Cancer Screening Study in High Risk Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03250078|
Recruitment Status : Recruiting
First Posted : August 15, 2017
Last Update Posted : April 9, 2019
|Condition or disease||Intervention/treatment|
|Pancreatic Neoplasms||Diagnostic Test: MRI/MRCP|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||A Pancreatic Cancer Screening Study in High Risk Individuals|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||November 2026|
|Estimated Study Completion Date :||November 2026|
FAMILIAL PANCREATIC CANCER and/or GENE MUTATION
An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
Diagnostic Test: MRI/MRCP
An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
- Early Stage Pancreatic Cancer or Precursor Lesions [ Time Frame: Through study completion, up to 3 years ]Incidence of Pancreatic Cancer or precursor lesions within a population of individuals with a strong family history of pancreatic cancer or known genetic mutation compared to the expected incidence in the general population.
- Serial Pancreatic MRI Screening [ Time Frame: Through study completion, up to 3 years ]Utility of MRI as a screening tool for Pancreatic Cancer in the study population.
- Serum Bio-bank [ Time Frame: Through study completion, up to 3 years ]Banking serum from participants to isolate circulating exosomes and circulating tumor DNA.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03250078
|Contact: Tammy Lo, APRN||Tammy.Lo@wchn.org|
|Contact: Pramila Krumholtz, RN||Pramila.Krumholtz@wchn.org|
|United States, Connecticut|
|Western Connecticut Health Network||Recruiting|
|Norwalk, Connecticut, United States, 06856|
|Contact: Tammy Lo, APRN 203-855-3551 Tammy.Lo@wchn.org|
|Contact: Pramila Krumholtz, RN 203-739-7997 Pramila.Krumholtz@wchn.org|
|Principal Investigator: Richard Frank, MD|
|Principal Investigator:||Richard Frank, MD||Western Connecticut Health Network|